Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

Suzette Delaloge, Sylvain Dureau, Véronique D’Hondt, Isabelle Desmoulins, Pierre‐Etienne Heudel, François P. Duhoux, Christelle Lévy, Florence Lerebours, Marie Ange Mouret-Reynier, Florence Dalenc, Jean‐Sébastien Frenel, Christelle Jouannaud, Laurence Venat‐Bouvet, Suzanne Nguyen, C. Callens, David Gentien, Audrey Rapinat, Helene Manduzio, Anne Vincent‐Salomon, Jérôme Lemonnier, Paul Cottu